Search results
Results from the WOW.Com Content Network
Antiplatelet drug. An antiplatelet drug (antiaggregant), also known as a platelet agglutination inhibitor or platelet aggregation inhibitor, is a member of a class of pharmaceuticals that decrease platelet aggregation [1] and inhibit thrombus formation. They are effective in the arterial circulation where classical Vitamin K antagonist ...
Clopidogrel, sold under the brand name Plavix among others, is an antiplatelet medication used to reduce the risk of heart disease and stroke in those at high risk. [ 10 ] It is also used together with aspirin in heart attacks and following the placement of a coronary artery stent (dual antiplatelet therapy). [ 10 ]
When in comparison to clopidogrel, there is evidence for increased risk of bleeding. [38] The PLATO trial [39] found that ticagrelor use, in conjunction with low-dose aspirin (where tolerated), had better all-cause mortality rates than the same treatment plan with clopidogrel (4.5% vs. 5.9%) in treating people with acute coronary syndrome ...
Aside from aspirin, three antiplatelet agents taken by mouth have been approved for use in acute coronary syndromes, clopidogrel, ticagrelor and prasugrel; all reduce platelet aggregation by inhibiting the P2Y 12 receptor, a type of adenosine phosphate receptor, on the surface of platelets. Not all three of them are equally indicated in all ...
Aspirin, beta blockers, nitroglycerin, statins [ 10 ] Frequency. 110 million (2015) [ 11 ] Deaths. 8.9 million (2015) [ 12 ] Coronary artery disease (CAD), also called coronary heart disease (CHD), or ischemic heart disease (IHD), [ 13 ] is a type of heart disease involving the reduction of blood flow to the cardiac muscle due to build-up of ...
In those who have had a stent, more than 12 months of clopidogrel plus aspirin does not affect the risk of death. [112] Beta blocker therapy such as metoprolol or carvedilol is recommended to be started within 24 hours, provided there is no acute heart failure or heart block. [19] [86] The dose should be increased to the highest tolerated. [109]
In this three-year study, the addition of vorapaxar to standard of care (aspirin and/or an ADP antagonist such as clopidogrel) significantly reduced the risk of the primary composite endpoint of cardiovascular death, heart attack, stroke, or urgent coronary revascularization by 12 percent compared to placebo plus standard of care. Vorapaxar ...
A transient ischemic attack (TIA), commonly known as a mini-stroke, is a minor stroke whose noticeable symptoms usually end in less than an hour. A TIA causes the same symptoms associated with a stroke, such as weakness or numbness on one side of the body, sudden dimming or loss of vision, difficulty speaking or understanding language, slurred speech, or confusion.